drugset / Trial / NCT02694289
Effects of Metformin in Heart Failure Patients
Withdrawn
Maya Guglin
RandomizedParallel-groupOpen-labelTreatment
Summary
Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with no negative impact on patient safety. This is a single center, prospective trial. Subjects will be randomized to initiate metformin (starting dose 500mg orally once daily up to a maximum dose of 2,500mg daily) OR be placed on insulin products for management of their type 2 diabetes mellitus.
Timeline
- Start
- 2016-11
- Primary completion
- 2018-09-10
- Completion
- 2018-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | — | — |
| Subject | Metformin | Small molecule | 2500 mg | Oral |
| Subject | Novalin | Unknown | — | — |
| Subject | insulin glargine | Protein / enzyme biologic | — | — |